Cancer Res Treat.  2015 Apr;47(2):173-181. 10.4143/crt.2014.055.

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis

• Hong J
• Kim SJ
• Ahn JS
• Song MK
• Kim YR
• Lee HS
• Yhim HY
• Yoon DH
• Kim MK
• Oh SY
• Park Y
• Mun YC
• Do YR
• Ryoo HM
• Lee JJ
• Lee JH
• Kim WS
• Suh C

• KMID: 2132795
• DOI: http://doi.org/10.4143/crt.2014.055

Abstract

PURPOSE
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
MATERIALS AND METHODS
Patients > or = 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.
RESULTS
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.
CONCLUSION
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Keyword

Burkitt lymphoma; Rituximab; CVAD protocol

MeSH Terms

Adult
Burkitt Lymphoma
Cytarabine
Doxorubicin
Drug Therapy
Follow-Up Studies
HIV
Humans
Korea
Lymphoma*
Methotrexate
Retrospective Studies
Survival Rate
Vincristine
Cytarabine
Doxorubicin
Methotrexate
Vincristine

Figure

• 

  Fig. 1. Kaplan-Meier curves of time to progression, event-free survival, and overall survival of the analyzed patients.

Reference

References

1. Linch DC. Burkitt lymphoma in adults. Br J Haematol. 2012; 156:693–703.

2. Huh J. Epidemiologic overview of malignant lymphoma. Korean J Hematol. 2012; 47:92–104.

3. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res. 1990; 55:133–270.

4. Ostronoff M, Soussain C, Zambon E, Ibrahim A, Bosq J, Bayle C, et al. Burkitt's lymphoma in adults: a retrospective study of 46 cases. Nouv Rev Fr Hematol. 1992; 34:389–97.

5. Mead GM, Sydes MR, Walewski J, Grigg A, Hatton CS, Pescosta N, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002; 13:1264–74.

6. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999; 17:2461–70.

7. Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013; 121:4861–6.

8. Wasterlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D'Amore F, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013; 24:1879–86.

9. Thomas DA, O'Brien S, Faderl S, Manning JT Jr, Romaguera J, Fayad L, et al. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep. 2011; 6:58–66.

10. Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol. 2012; 156:234–44.

11. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106:1569–80.

12. Suh C, Kim WS, Kim JS, Park BB. Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. Blood Res. 2013; 48:171–7.

13. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25:579–86.

14. Soussain C, Patte C, Ostronoff M, Delmer A, Rigal-Huguet F, Cambier N, et al. Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood. 1995; 85:664–74.

15. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol. 2001; 19:4014–22.

16. Mead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008; 112:2248–60.

17. Choi MK, Jun HJ, Lee SY, Kim KH, Lim DH, Kim K, et al. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. Ann Hematol. 2009; 88:1099–106.

18. Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011; 22:1859–64.

19. Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, et al. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013; 98:1718–25.

20. Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol. 2010; 92:732–43.

21. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52:e56–93.

22. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001; 97:2998–3003.

23. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, et al. Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012; 10:858–914.

24. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, La-Casce AS, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009; 9:307–10.

25. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013; 369:1915–25.